AstraZeneca's Promising Biomarker Data and Phase III Trials: Buy Rating Affirmed

Bank of America Securities' Sachin Jain maintains Buy rating on AstraZeneca (AZN) with a £14,500.00 price target, citing positive biomarker data from datopotamab TL01 study in second-line lung cancer and potential catalysts like AVANZAR phase III trial in 2025.